Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096665 Target Snapshot

Pyruvate dehydrogenase kinase · PROTEIN FAMILY · Homo sapiens

452Compounds
25Assays
0Approved Drugs
493.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q15119. Start with lactic acidosis, then reuse UniProt Q15119 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with lactic acidosis, then reuse UniProt Q15119 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
lactic acidosis

Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with lactic acidosis because it currently carries late clinical support. Linked drugs include SODIUM DICHLOROACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Protein anchor
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial

[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial

Review this target as Pyruvate dehydrogenase kinase, mapped to UniProt Q15119. ChEMBL maps the protein component as [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial. Sequence length is 407 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q15119 Protein 407 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Pyruvate dehydrogenase kinase as ChEMBL target CHEMBL2096665, mapped to UniProt Q15119. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Pyruvate dehydrogenase kinase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2096665
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q15119
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Pyruvate dehydrogenase kinase is the right protein anchor across sources, using UniProt Q15119 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why lactic acidosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial
UniProt AccessionQ15119
Component TypeProtein
Sequence Length407 aa

[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Pyruvate dehydrogenase kinase, mapped to UniProt Q15119. ChEMBL maps the protein component as [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial. Sequence length is 407 aa.

Mapped IDQ15119
Review namePyruvate dehydrogenase kinase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Pyruvate dehydrogenase kinase shows late clinical disease relevance led by lactic acidosis. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
lactic acidosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Late clinical Phase III
pyruvate dehydrogenase deficiency
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Clinical signal Phase II
head and neck squamous cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Clinical signal Phase II
heart disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSODIUM DICHLOROACETATE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with lactic acidosis because it currently carries late clinical support. Linked drugs include SODIUM DICHLOROACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaselactic acidosis
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50485.0
EC508.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL73068 8.15 IC50 7.1 Preclinical
CHEMBL74582 8.1 IC50 8.0 Preclinical
CHEMBL73204 8.08 IC50 8.4 Preclinical
CHEMBL3714823 8.0 IC50 10.0 Preclinical
CHEMBL3714889 8.0 IC50 10.0 Preclinical
CHEMBL3714928 8.0 IC50 10.0 Preclinical
CHEMBL3715044 8.0 IC50 10.0 Preclinical
CHEMBL3715049 8.0 IC50 10.0 Preclinical
CHEMBL3715072 8.0 IC50 10.0 Preclinical
CHEMBL3715313 8.0 IC50 10.0 Preclinical
Distribution

pChEMBL Value Distribution

37
5.0
13
5.5
127
6.0
21
6.5
168
7.0
12
7.5
47
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

25
Total Assays
444
Tested Compounds
2
Assay Types
Binding — 24 assays, 444 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 60 6.0
protein format 9 122 6.3
assay format 1 262 6.8
Functional — 1 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1 8 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine